Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

VABOMERE Shows Higher Cure Rate in Patients with CRE Infections Vs. Best Available Therapy

OCT 18, 2017 | CONTAGION® EDITORIAL STAFF


Michael N. Dudley, PharmD, senior vice president and head of R&D at the Medicines Company, discusses the results of the TANGO II study of VABOMERE, a new beta-lactam that combines meropenem and vaborbactam. In patients with carbapenem-resistant Enterobacteriaceae (CRE), VABOMERE was associated with a higher overall cure and lower mortality compared with the best available therapy.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x